YCBD - cbdMD initiates clinical study exploring cannabinoid blend in humans

cbdMD (YCBD +0.7%) has commenced a preclinical human study with researchers at the University of South Carolina. The study will explore the effects of cbdMD’s proprietary broad spectrum cannabinoid blend on sleep, mood, and pain in healthy subjects to further support the efficacy of the Company’s products. The studies will also be measuring key safety markers in healthy humans to augment YCBD's safety dossiers for regulatory submissions. cbdMD anticipates that these favorable outcomes will be the basis for future drug research and applications by its therapeutics division.

For further details see:

cbdMD initiates clinical study exploring cannabinoid blend in humans